Gradalis announces positive results from phase 2b VITAL trial of Vigil to treat patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer: Dallas Friday, January 16, ...
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...
Dive into a comprehensive comparison of Vanguard and Fidelity, examining costs, products, services and which might suit your financial strategy best Written By Written by Staff Money Writer, WSJ | Buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback